İ. Çelik

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Annals of Oncology · 2011 · 778 citations · Full text

Biomarker Status, Oncology, Gastrointestinal Oncology +9

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Journal of Clinical Oncology · 2008 · 241 citations

Kras Mutations, Surgical Oncology, Gastrointestinal Oncology +15

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

Jan B. Vermorken, Amanda Psyrri, Frédéric Peyrade et al. · Annals of Oncology · 2014 · 207 citations · Full text

cTnT can be a useful marker for early detection of anthracycline cardiotoxicity

Erol Akgül, Kudret Aytemir, Serdar Aksöyek et al. · Annals of Oncology · 2005 · 164 citations · Full text

Useful Marker, Oncology, Engineering +9

The effects of particle size distribution and surface area upon cement strength development

İ. Çelik · Powder Technology · 2008 · 158 citations

Geotechnical Engineering, Cement Strength Development, Cementation +8